BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22186618)

  • 1. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.
    Becker ML; Elens LL; Visser LE; Hofman A; Uitterlinden AG; van Schaik RH; Stricker BH
    Pharmacogenomics J; 2013 Jun; 13(3):251-6. PubMed ID: 22186618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
    de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
    Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.
    Willke RJ; Zhou S; Vogel RA
    Curr Med Res Opin; 2008 Oct; 24(10):2873-82. PubMed ID: 18761783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
    Stoekenbroek RM; Boekholdt SM; Fayyad R; Laskey R; Tikkanen MJ; Pedersen TR; Hovingh GK;
    Heart; 2015 Mar; 101(5):356-62. PubMed ID: 25595417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
    Ballantyne CM; Blazing MA; King TR; Brady WE; Palmisano J
    Am J Cardiol; 2004 Jun; 93(12):1487-94. PubMed ID: 15194018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
    Rogers SL; Magliano DJ; Levison DB; Webb K; Clarke PJ; Grobler MP; Liew D
    Clin Ther; 2007 Feb; 29(2):242-52. PubMed ID: 17472817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No changes of cholesterol levels with a commercially available glucosamine product in patients treated with lipid lowering drugs: a controlled, randomised, open cross-over trial.
    Eggertsen R; Andreasson A; Andrén L
    BMC Pharmacol Toxicol; 2012 Oct; 13():10. PubMed ID: 23050945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
    MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.
    Foody JM; Joyce AT; Jeffers BW; Liu LZ; Benner JS
    Am J Ther; 2011; 18(2):110-6. PubMed ID: 20216383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
    Tomassini JE; Mazzone T; Goldberg RB; Guyton JR; Weinstock RS; Polis A; Jensen E; Tershakovec AM
    Diabetes Obes Metab; 2009 Sep; 11(9):855-64. PubMed ID: 19508464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
    van den Akker JM; Bredie SJ; Diepenveen SH; van Tits LJ; Stalenhoef AF; van Leusen R
    J Nephrol; 2003; 16(2):238-44. PubMed ID: 12768071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenomics; 2009 Nov; 10(11):1743-51. PubMed ID: 19891551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
    Lampl Y; Lorberboym M; Gilad R; Vysberg I; Tikozky A; Sadeh M; Boaz M
    Clin Neuropharmacol; 2010 May; 33(3):129-34. PubMed ID: 20502132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.